Dexcom (NASDAQ:DXCM) Director Jay S. Skyler sold 30,000 shares of the company’s stock in a transaction that occurred on Monday, May 14th. The shares were sold at an average price of $88.00, for a total value of $2,640,000.00. Following the completion of the transaction, the director now directly owns 4,553 shares in the company, valued at approximately $400,664. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink.
Shares of NASDAQ:DXCM opened at $86.91 on Friday. Dexcom has a 1 year low of $86.75 and a 1 year high of $87.40. The company has a quick ratio of 5.42, a current ratio of 5.83 and a debt-to-equity ratio of 0.79.
Dexcom (NASDAQ:DXCM) last issued its quarterly earnings results on Wednesday, May 2nd. The medical device company reported ($0.32) earnings per share (EPS) for the quarter, hitting the Zacks’ consensus estimate of ($0.32). The business had revenue of $184.40 million for the quarter, compared to the consensus estimate of $172.66 million. Dexcom had a negative return on equity of 9.32% and a negative net margin of 4.30%. The firm’s quarterly revenue was up 29.6% compared to the same quarter last year. During the same quarter in the prior year, the business posted ($0.49) earnings per share. research analysts forecast that Dexcom will post -0.52 earnings per share for the current fiscal year.
Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Rockefeller Capital Management L.P. bought a new position in shares of Dexcom in the 1st quarter valued at $67,132,000. Bridger Management LLC bought a new position in shares of Dexcom in the 4th quarter valued at $48,826,000. Point72 Asset Management L.P. lifted its stake in shares of Dexcom by 429.3% in the 1st quarter. Point72 Asset Management L.P. now owns 979,175 shares of the medical device company’s stock valued at $72,616,000 after acquiring an additional 794,175 shares during the last quarter. OppenheimerFunds Inc. lifted its stake in shares of Dexcom by 96.5% in the 4th quarter. OppenheimerFunds Inc. now owns 1,495,535 shares of the medical device company’s stock valued at $85,829,000 after acquiring an additional 734,325 shares during the last quarter. Finally, AXA lifted its stake in shares of Dexcom by 44.9% in the 4th quarter. AXA now owns 1,911,206 shares of the medical device company’s stock valued at $109,684,000 after acquiring an additional 592,275 shares during the last quarter.
Several equities analysts have recently commented on the company. TheStreet raised Dexcom from a “d” rating to a “c-” rating in a research report on Thursday, May 10th. Bank of America assumed coverage on Dexcom in a research report on Friday, May 11th. They issued a “buy” rating and a $100.00 target price on the stock. Morgan Stanley upped their target price on Dexcom from $56.00 to $70.00 and gave the company an “equal weight” rating in a research report on Friday, May 4th. ValuEngine raised Dexcom from a “hold” rating to a “buy” rating in a research report on Thursday, May 3rd. Finally, Canaccord Genuity upped their target price on Dexcom from $81.00 to $85.00 and gave the company a “buy” rating in a research report on Thursday, May 3rd. Two investment analysts have rated the stock with a sell rating, seven have issued a hold rating, twelve have given a buy rating and one has issued a strong buy rating to the company. Dexcom has a consensus rating of “Buy” and a consensus target price of $69.79.
Dexcom Company Profile
DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company offers its systems for ambulatory use by people with diabetes; and for use by healthcare providers. Its products include DexCom G5 mobile continuous glucose monitoring system to communicate directly to patient's mobile device; DexCom G4 PLATINUM system for continuous use by adults with diabetes; and DexCom Share, a remote monitoring system.
Receive News & Ratings for Dexcom Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dexcom and related companies with MarketBeat.com's FREE daily email newsletter.